TEST AND PRICE LIST FOR NEXT GENERATION SEQUENCING
|
|
|
- Hubert Mason
- 2 years ago
- Views:
Transcription
1 AIP ALK APC Mutation Detection Techniques Ai Saple Type TAT ATM BAP1 BLM BMPR1A BRCA1 BRCA2 BRIP1 BUB1B CDC73 CDH1 CDK4 CDKN1C CDKN2A CEBPA CEP57 CHEK2 CYLD DDB2 DICER1 DIS3L2 EGFR EPCAM ERCC2 ERCC3 ERCC4 ERCC5 EXT1 EXT2 TEST AND PRICE LIST FOR NEXT GENERATION SEQUENCING Price ( Euro) Producer
2 EZH2 FANCA FANCB FANCC FANCD2 FANCE FANCF FANCG FANCI FANCL FANCM FH FLCN GATA2 GPC3 HNF1A HRAS KIT MAX MEN1 MET MLH1 MSH2 MSH6 MUTYH NBN NF1 NF2 NSD1 PALB2 PHOX2B PMS1 PMS2 PRF1 PRKAR1A
3 PTCH1 PTEN RAD51C RAD51D RB1 RECQL4 RET RHBDF2 RUNX1 SBDS SDHAF2 SDHB SDHC SDHD SLX4 SMAD4 SMARCB1 STK11 SUFU TMEM127 TP53 TSC1 TSC2 VHL WRN WT1 XPA XPC Lung Panel EGFR, KRAS, EML4ALK,AKT1, MET, ALK, NRAS BRAF, PIK3CA, CTNNB1 PTEN, MAP2K1, P53
4 Colon Panel KRAS, BRAF, AKT1, NRAS, APC, PIK3CA CTNNB1, PTEN, EGFR SRC, FBXW7, P53, MET Melanoa Panel BRAF, KIT, BRAF, MAP2K1, GNA11 NRAS, GNAQ, PIK3CA KIT, PTEN, KRAS Gastric Panel (GIST) KIT, PDGFRA,AKT1, PIK3CA FGFR2, P53 Ovarian Panel AKT1, PTEN ERBB2, P53 BRCA MASTR Dx HNPCC MASTR FAP MASTR CFTR MASTR v2 CFTR MAQ CFTR HP MARFAN MASTR FMF MASTR v2 DMD MASTR MODY MASTR ADH MASTR HCM MASTR HNF4A GCK HNF4A HNF1A HNF4A PDK1 HNF4A 15 days days days 1200 Tugen Tugen Tugen Tugen
5 HNF1B HNF4A FMF Gene Mutations Tugen Tugen
Next-generation sequencing can replace Sanger sequencing in clinical diagnostics.
Next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Birgit Sikkema-Raddatz Department of Genetics, University Medical Center Groningen The Netherlands Groningen GRONINGEN
La diagnostica molecolare nelle neoplasie colo-rettali. A do Scarpa. U iversita di Vero a
La diagnostica molecolare nelle neoplasie colo-rettali C-NET A do Scarpa e Dipartime to Pato ogia e U iversita di Vero a La stessa malattia puo avere diverse patogenesi cucchiaio moneta forchetta Gastrointestinal
patient guide CancerNext TM - A Genetic Test for Hereditary Cancer
patient guide CancerNext TM - A Genetic Test for Hereditary Cancer What is hereditary cancer? Cancer affects many people in the U.S. more than 1.6 million people are estimated to be diagnosed with cancer
Nuovi Scenari in Oncologia. G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012
Nuovi Scenari in Oncologia G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012 WHAT is cancer? «Cancer is a genetic disease of the somatic cell» [B. Vogelstein] Ten years ago Now [Cell.
Corporate Medical Policy
Corporate Medical Policy Genetic Cancer Susceptibility Panels Using Next Generation Sequencing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_cancer_susceptibility_panels_using_next_generation_sequencing
HEREDITARY CANCER GENE PANEL DG 2.3.x
HEREDITARY CANCER GENE PANEL DG 2.3.x Gene Median % covered % covered Associated Phenotype description and OMIM ID coverage >10x >20x ALK 99,5 100% 98% {Neuroblastoma, susceptibility to, 3}, 613014 APC
BRCAplus: A Genetic Test for Hereditary Breast Cancer
BRCAplus: A Genetic Test for Hereditary Breast Cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer Familial,
A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?
A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is
CancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN
Page 1 of 7 POSITIVE TEST RESULTS Biomarker Result DETECTED NEGATIVE TEST RESULTS FDA Approved Therapies Targeting Molecular Pathway TEST DESCRIPTION: CancerTREATMENT NGS+ uses Next Generation Sequencing
Launching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment
Launching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment Arthur L. Beaudet, M.D. Department of Molecular and Human Genetics Baylor College of Medicine ORIGIN AND PRECEDENT Decades of experience
Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
Test Information Sheet
Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: High/Moderate Risk Panel Sequence
1199 SEIU Benefit Funds Laboratory Management Program PRIOR AUTHORIZATION CODE LIST FOR OUTPATIENT MOLECULAR AND GENOMIC LABORATORY TESTS
1199 SEIU Benefit Funds Laboratory Management Program PRIOR AUTHORIZATION CODE LIST FOR OUTPATIENT MOLECULAR AND GENOMIC LABORATORY TESTS Effective January 1, 2016 Administered by evicore healthcare Refer
Section: Genetic Testing Last Reviewed Date: October 2015. Policy No: 73 Effective Date: November 1, 2015
Medical Policy Manual Topic: Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Date of Origin: July 2014 Section: Genetic Testing Last Reviewed Date: October 2015 Policy No: 73 Effective
Hereditary Breast Cancer Panels. High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel
P A T I E N T G U I D E Hereditary Breast Cancer Panels High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel B a y l o r M i r a c a G e n e t i c s L a b o r a t
NEIGE. diagnosis In oncogenetics. Nicolas Sévenet 02 juillet 2012. n.sevenet@bordeaux.unicancer.fr
NEIGE g for molecular NExt g generation sequencing diagnosis In oncogenetics Nicolas Sévenet 02 juillet 2012 n.sevenet@bordeaux.unicancer.fr t@b d i f Reports 15 years Next generation sequencing 06/2011
Oncomine Cancer Panel Patient Test Report
Oncomine Cancer Panel Patient Test Report SUBJECT NFORMATON Pre-Screening Subject No.: Life Technologies Clinical Services Lab 910 Riverside Parkway, Suite 60 West Sacramento, CA 95605 Ph: (888) 734-8588
PREDICT. Comprehensive Hereditary Cancer Risk Assessment
PREDICT Comprehensive Hereditary Cancer Risk Assessment 1451 NORTHSIDE DRIVE NW SUITE A ATLANTA, GA 30318 (tel) 404.228.5027 (fax) 404.343.0087 LABSOLUTIONS.COM LABSOLUTIONS is pleased to offer its clients
GENETIC COUNSELING FOR BREAST CANCER
GENETIC COUNSELING FOR BREAST CANCER Anne Heun, MS, CGC Unity Point Health Des Moines Throckmorton Surgical Symposium 2016 Outline High risk genes Moderate risk genes Appropriate referrals or testing candidates
Beyond BRCA the Future is Now
Beyond BRCA the Future is Now Richard P. Frieder, MD Medical Director, Intelegene Assistant Clinical Professor Department of Obstetrics and Gynecology David Geffen School of Medicine, UCLA University of
Breast Cancer Risk Assessment and Strategies for Risk Reduction and Prevention
Breast Cancer Risk Assessment and Strategies for Risk Reduction and Prevention Mary Cianfrocca, DO, FACP Division Chief of Internal Medicine, Banner MD Anderson Cancer Center Adjunct Associate Professor,
Test Information Sheet
Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: Breast/Ovarian Cancer Panel Sequence
Big Data Part I: Data-Driven Life Sciences Innovation, Personalized Medicine and Research
Big Data Part I: Data-Driven Life Sciences Innovation, Personalized Medicine and Research December 9, 2014 www.mwe.com Boston Brussels Chicago Düsseldorf Frankfurt Houston London Los Angeles Miami Milan
Gene Panels: The Next Step in Hereditary Cancer Evaluation
Gene Panels: The Net Step in Hereditary Cancer Evaluation Faculty Julia Smith, MD, PhD (Moderator) Clinical Director Cancer Screening Program at the Laura and Isaac Perlmutter Cancer Center at NYU Medical
Test Information Sheet
Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: Breast/Ovarian Cancer Panel Sequence
A Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services. Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD
A Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD Importance of Family History Increasing awareness of
Ion AmpliSeq Technology
Ion AmpliSeq Technology Dr. Franziska Freund Sr. Sequencing Sales Specialist 26.06.2015 1 The world leader in serving science Ion AmpliSeq Technology: As Simple As PCR Your targets, your genome, your panel
Ovarian Cancer Genetic Testing: Why, When, How?
Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine
Cancer Genomics & Precision Medicine in the 21 st Century. Lee J. Helman, MD Scientific Director for Clinical Research CCR, NCI
Cancer Genomics & Precision Medicine in the 21 st Century Lee J. Helman, MD Scientific Director for Clinical Research CCR, NCI Outline Define terms Describe vision for how genetic characterization of tumors
Microsatellite Instability (MSI) A New Paradigm in Cancer Treatment. Lynch Syndrome OUTLINE. GI Molecular Pathology
OUTLINE GI Molecular Pathology Microsatellite Instability and Lynch Syndrome GI Cancer Genotyping KRAS Mutations in Colorectal Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General
Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests
Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests James H. Doroshow, M.D. NCI Deputy Director for Clinical and Translational Research NCI Workshop: Evidence Needed
TABLE OF CONTENTS. Genoptix Medical Laboratory 2110 Rutherford Road Carlsbad, CA Phone: Fax:
TESTING DIRECTORY TABLE OF CONTENTS Genoptix Medical Laboratory 2110 Rutherford Road Carlsbad, CA 92008 Phone: 760.268.6200 Fax: 760.268.6201 Client Services Phone: 800.755.1605 Fax: 888.755.1604 CLIA
BRCA1/2 and Lynch Syndrome Analyses with CancerNext. POSITIVE: Pathogenic Mutation Detected
SAMPLE REPORT Ordered By Contact ID:405956 Org ID:249 Physician: Sample Doctor, A Ph:111-222-3333 Client: Sample Organization (00403) Organization Address City CA 99999 US Fx:444-555-6666 Patient Name:
J Clin Oncol 32:2001-2009. 2014 by American Society of Clinical Oncology INTRODUCTION
VOLUME 32 NUMBER 19 JULY 1 2014 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment Allison W. Kurian,
Approaches to Integrating Next Generation Sequencing into the Electronic Health Record
AMIA Webinar April 16, 2014 Approaches to Integrating Next Generation Sequencing into the Electronic Health Record Peter Tarczy-Hornoch, University of Washington On behalf of the Clinical Sequencing Exploratory
High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma
High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma The Harvard community has made this article openly available. Please share how this access benefits
Hereditary Breast Cancer Testing. Diagnostic
Hereditary Cancer Testing Diagnostic New solutions for hereditary breast cancer. Identifying and understanding the genetic contribution to breast cancer allows for individualized disease management and
2014 CPT Code Updates
2014 CPT Code Updates This publication is a summary of The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory effective January 1, 2014.
Prevalenza delle mutazioni TMEM127 nel feocromocitoma sporadico
Prevalenza delle mutazioni TMEM127 nel feocromocitoma sporadico Giuseppe Opocher Veneto Institute of Oncology and Department of Medical and Surgical Sciences, University of Padova, Italy Sympathetic paraganglia
Genetics and Breast Cancer. Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service
Genetics and Breast Cancer Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service Overview Background/Our Team What is the difference between sporadic/familial cancer? How
Target enrichment using selector probes. Department of Genetics and Pathology, Uppsala University
Target enrichment using selector probes Mats Nilsson Department of Genetics and Pathology, Uppsala University Target enrichment using selector probes Even with radically improved sequencing throughput,
Umeå University. Access to the published version may require subscription.
Umeå University This is an accepted version of a paper published in Acta Oncologica. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.
MEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 02/24/2015 02/24/2016 04/21/2015 Policy Name Policy Number Genetic Testing, Genetic Screening and Genetic
The Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine
The Genetics of Early- Onset Breast Cancer Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine All cancers are genetic BUT Not all cancers are hereditary
Germline testing for hereditary Cancer Syndromes. Update 2015
Germline testing for hereditary Cancer Syndromes Update 2015 Topics to be discussed Case Presentation Standard Indications for testing common syndromes Next Generation Sequencing and panel testing Unique
PATOLOGIA MOLECULAR DEL CANCER GINECOLOGICO. Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.
PATOLOGIA MOLECULAR DEL CANCER GINECOLOGICO Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA. Carcinoma de Endometrio Cáncer de Ovario Endometrial carcinoma
Frequency of Mutations in Individuals With Breast Cancer Referred for BRCA1 and BRCA2 Testing Using Next-Generation Sequencing With a 25-Gene Panel
Frequency of Mutations in Individuals With Breast Cancer Referred for BRCA1 and BRCA2 Testing Using Next-Generation Sequencing With a 25-Gene Panel Nadine Tung, MD 1,2 ; Chiara Battelli, MD 1 ; Brian Allen,
Hereditary Breast Cancer Testing. clinician guide
Hereditary Breast Cancer Testing clinician guide Ambry s test offerings are designed to provide flexible, comprehensive options tailored to your patients personal and family histories. New Solutions for
BRCA and Other Genetic Abnormalities
Genes and Cancer BRCA and Other Genetic Abnormalities Anne Heun, MS, CGC Certified Genetic Counselor John Stoddard Cancer Center All cancer is GENETIC Tumor suppressor gene: a.k.a. anti-oncogene Important
Breast and Ovarian Cancer
Breast and Ovarian Cancer Hereditary Breast and Ovarian Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS Hereditary Breast and Ovarian Cancer Panel
Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
Molecular Human Genetics. Cancer, Tumor suppressor genes, Oncogenes
Youtube ARCC http://www.youtube.com/watch?v=3pobqrfz0no It's Our Time - American Association for Cancer Research (AACR) Molecular Human Genetics Cancer, Tumor suppressor genes, Oncogenes Hum 2014/15 1
6/10/2015. Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond. Hereditary Cancers. BRCA1 and BRCA2 Review
Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond Arturo Anguiano MD, FACMG International Medical Director, Medical Affairs Vice Chairman, Genetics; Medical Director,
Avances en la Patología Molecular del Cáncer de Endometrio
CURSO DE PATOLOGÍA GINECOLÓGICA II Actualizaciones en patología cervical y endometrial Avances en la Patología Molecular del Cáncer de Endometrio José Palacios Hospital Universitario Ramón y Cajal. Madrid
Evalua&ng tumor exome sequencing in the oncology clinic:
Evalua&ng tumor exome sequencing in the oncology clinic: Lessons from the BASIC3 study GBM Cancer Risk? A Clinical Sequencing Exploratory Research (CSER) project Supported by NHGRI/NCI 1U01HG006485 ISMB2014
Colon Cancer Syndromes. Robin B. Mendelsohn MD Memorial Sloan Kettering Cancer Center Department of Medicine Gastroenterology and Nutrition Service
Colon Cancer Syndromes Robin B. Mendelsohn MD Memorial Sloan Kettering Cancer Center Department of Medicine Gastroenterology and Nutrition Service Background: Etiology of Colorectal Cancer (CRC) Sporadic:
Common Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
CALL FOR PARTNERSHIP MULTIPLI PROGRAM
CALL FOR PARTNERSHIP MULTIPLI PROGRAM I. Introduction The MULTIPLI program, coordinated by Inserm (the French National Institute of Health and Medical Research) and the Cancer Institute of the French National
Factsheet Renal Cancer Panel. minimum DNA (µg) minimum EDTA blood (ml) minimum filtercards (pcs)
Renal cancer panel Centogene ID: 5235 Gene(s) name (OMIM, HGNC): Gene Renal Cancer Panel EPCAM, FH, FLCN, HNF1A, HNF1B, MET, MITF, MLH1, MSH2, MSH6, PMS1, PMS2, PTEN, SDHB, SDHD, TSC1, TSC2, VHL, WT1 1.
Genomic instability in cancers and cancer predispositions. Popova Tatiana Inserm U830 Institut Curie
Genomic instability in cancers and cancer predispositions Popova Tatiana Inserm U830 Institut Curie Time-scale in a tumor genome discovery Bovery HYP Cancer genome Knudson 2 hit HYP Tumor DNA has transforming
Submitted 12 September 2014; accepted 12 September 2014; advance online publication 13 November 2014. doi:10.1038/gim.2014.147. Genetics in medicine
American College of Medical Genetics and Genomics ACMG Practice Guidelines A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors:
Progress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
Inherited breast cancer Inherited colon cancer Other inherited cancer predispositions
13.40-14.00 Inherited breast cancer 14.00-14.20 Inherited colon cancer 14.20-14.40 Other inherited cancer predispositions Dr Anne De Leener Centre de Génétique Humaine 1. INHERITED BREAST CANCER Introduction
Cardio Gene panel experience. Jan Jongbloed Laboratory Specialist Clinical Genetics Genome Diagnostics Department of Genetics UMCG Groningen
Cardio Gene panel experience Jan Jongbloed Laboratory Specialist Clinical Genetics Genome Diagnostics UMCG Groningen CardioGenetics: Rowida Almomani Ludolf Boven Anne Herkert Yvonne Hoedemaekers Irene
WHITE PAPER SEPT 2015
WHITE PAPER SEPT 2015 LIQUID BIOPSY FOR THE DETECTION AND MONITORING OF CANCER: ANALYSIS OF 96 HOTSPOT MUTATIONS VIA PLASMA DERIVED CIRCULATING TUMOR DNA PATHWAY GENOMICS CANCER AND SOMATIC MUTATIONS The
Molecular Pathology/Molecular Diagnostics/Genetic Testing
Policy Number GEN01252012RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 01/28/2015 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable
Examples of The Cancer Genome Atlas (TCGA) Analyses in GenePool
Examples of The Cancer Genome Atlas (TCGA) Analyses in 1. RNA-Seq 2. mirna-seq 3. Protein Expression 4. Somatic Mutations 5. Copy Number 6. DNA Methylation RNA-Seq All primary tumor samples (1,097 of 1,218)
July 14, 2014. Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
ASCP s Statements before the Centers for Medicare and Medicaid Services Regarding Recommendations for Crosswalking/Gapfilling New CPT s for the CLFS for CY 2015 and the Revaluation of the Clinical Laboratory
Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment
Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment Policy #: 133 Latest Review Date: April 2015 Category: Laboratory Policy Grade: D
The Role of Next Generation Sequencing in Solid Tumor Mutation Testing
The Role of Next Generation Sequencing in Solid Tumor Mutation Testing Allie H. Grossmann MD PhD Department of Pathology, University of Utah Division of Anatomic Pathology & Oncology, ARUP Laboratories
Next Generation Sequencing in Early-Phase Clinical Trials in Cancer Filip Janku
11 th International Congress on Targeted Anticancer Therapies Paris March 4-6, 2013 Next Generation Sequencing in Early-Phase Clinical Trials in Cancer Filip Janku Investigational Cancer Therapeutics (Phase
Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer
/, Vol. 7, No. 7 Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer Po-Han Lin 1,2, Wen-Hung Kuo 3, Ai-Chu Huang 2, Yen-Shen Lu 4, Ching-Hung Lin 4, Sung-Hsin
Introducing Dorevitch s Genomic Diagnostics
Genetic Testing Introducing Dorevitch s Genomic Diagnostics As one of Australia s longest running and nationally coordinated DNA testing organisations, Dorevitch s Genomic Diagnostics perform specialised
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
PRACTICE GUIDELINES nature publishing group 223 CME ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes Sapna Sy nga l, MD, M PH, FAC G 1, 2, 3, R and
Towards new classifications and individualised treatment for cancer patients
Towards new classifications and individualised treatment for cancer patients Professor Thomas TURSZ General Director Institut Gustave Roussy Villejuif Paris - France Workshop Chemores Milano January 21
Metastatic Hereditary Breast Cancer: What s New? Melinda Telli, M.D. Assistant Professor of Medicine Stanford University School of Medicine
Metastatic Hereditary Breast Cancer: What s New? Melinda Telli, M.D. Assistant Professor of Medicine Stanford University School of Medicine Outline Treatment principles in metastatic breast cancer Update
RUO Molecular Probes For in situ hybridization
RUO Molecular Probes For in situ hybridization Molecular Probes The RUO (Research Use Only) molecular probes from Roche deliver highly specific staining on our fully automated platforms. Utilizing a unique
Molecular pathology of thyroid cancers
Molecular pathology of thyroid cancers Peter Lakatos 1st Department of Medicine Semmelweis University Thyroid nodules 4-7% of population with palpable nodules More frequent in women Incidence increasing
CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE
CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE Agenda Introduction to Cancer Research UK CRUK Stratified Medicine Programme Key Challenges and Lessons
Disclosures. Personalized Meds from the molecular onco-pathology s perspective
1 FIGON DMD Symposium From Protocol towards Personalized Tailored Therapy Ede, October 6th 2015 Personalized Meds from the molecular onco-pathology s perspective Diagnostic in Pathology in 2015-2020 Molecular
Chronic Lymphocytic Leukemia - Disease and Current Therapies from a Medical Perspective
Chronic Lymphocytic Leukemia - Disease and Current Therapies from a Medical Perspective C. Reinhardt Medical Clinic I, Hematology/Oncology CECAD, Research Area C Clinical and Molecular Oncology CLL - an
Immunophenotyping of hereditary breast cancer
Immunophenotyping of hereditary breast cancer Petra van der Groep Cover design: P. van der Groep Lay-out: Gildeprint Drukkerijen - Enschede, The Netherlands Printed by: Gildeprint Drukkerijen - Enschede,
Application of Molecular Diagnosis: Present and Future
Application of Molecular Diagnosis: Present and Future Dong Jun Lim, MD., PhD. Associate Professor Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary s Hospital,
The Future of Clinical Chemistry and Laboratory Medicine, The Diagnostics Industry View
The Future of Clinical Chemistry and Laboratory Medicine, The Diagnostics Industry View Peng Yin, M.D., Ph.D., Director, Global Scientific Affairs Abbott Diagnostic Division (ADD) Agenda Lack of perceived
Epithelial Ovarian Cancer
Epithelial Ovarian Cancer Fred Ueland, MD University of Kentucky Gynecologic Oncology Risk Factors Incessant ovulation Early menarche, late menopause, low parity Family history Acquired genetic mutations
Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment
Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment Policy #: 133 Latest Review Date: April 2015 Category: Laboratory Policy Grade: D
Clinical Use of Molecular Diagnos@cs in the Treatment of Lung Cancer
Clinical Use of Molecular Diagnos@cs in the Treatment of Lung Cancer Tianhong Tina Li, MD, PhD (thli@ucdavis.edu) Associate Professor of Clinical Medicine, School of Medicine Disclosures Grants/Research
Stato dell arte e prospettive delle terapie a bersaglio molecolare nel carcinoma polmonare
Stato dell arte e prospettive delle terapie a bersaglio molecolare nel carcinoma polmonare Giorgio V. Scagliotti Università di Torino Dipartimento di scienze cliniche & biologiche giorgio.scagliotti@unito.it
GeneQuery Human Epithelial Cell Biology qpcr Array Kit (GQH-EPI) Catalog #GK005
GeneQuery Human Epithelial Cell Biology qpcr Array Kit (GQH-EPI) Catalog #GK005 Product Description ScienCell's GeneQuery Human Epithelial Cell Biology qpcr array kit (GQH-EPI) is designed to facilitate
Een behandeling op maat voor iedere patient: wat betekent dat in de praktijk? Emile Voest
Een behandeling op maat voor iedere patient: wat betekent dat in de praktijk? Emile Voest Need for personalised cancer treatment Scenario: patient with metastasized colorectal cancer Doctor suggests treatment
Hereditary Colon Cancer
Hereditary Colon Cancer Eric D. Libby, MD Winchester Hospital Family History of Colon Cancer Most colon cancer occurs in patients without a family history 70-80% is sporadic Only 20-30% of cancer patient
Molecular Diagnosis of Gastrointestinal Tumors
Molecular Diagnosis of Gastrointestinal Tumors Zoltan Szentirmay National Institute of Oncology Center of Surgical and Molecular Tumor Pathology EEA and Norwegian Financial Mechanisms in Hungary, Development
The Next Generation of Genomic Testing: Billing and Reimbursement in the Genomic Era
The Next Generation of Genomic Testing: Billing and Reimbursement in the Genomic Era Co-Moderators: Jerry Feldman, MD, PhD, FACMG Wayne State University School of Medicine Detroit Medical Center University
Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry
The American Journal of Surgery (2013) 205, 608-612 North Pacific Surgical Association Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer
Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth
Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes Dr. med. Henrik Csaba Horváth Why is risk stratification for colorectal cancer (CRC)
COLON CANCER: PAST, PRESENT, AND FUTURE AND FAMILIAL SYNDROMES. Eun Lee, MD, Professor & Director of Anatomic Pathology
COLON CANCER: PAST, PRESENT, AND FUTURE AND FAMILIAL SYNDROMES Eun Lee, MD, Professor & Director of Anatomic Pathology MCC Affiliate Network Meeting Etiology for colon cancer Past, Present, and Future
Genomic Clinical Trials: NCI Initiatives
Genomic Clinical Trials: NCI Initiatives James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute National Cancer Advisory Board Washington, DC December
Genetics of Pancreatic Cancer
Genetics of Pancreatic Cancer Gloria M. Petersen, Ph.D. Mayo Clinic Rochester, Minnesota Pancreatic Cancer Action Network Bloomington, MN Topics Is family history a risk factor for pancreatic cancer? Why
Molecular Stratification of Cancer in the
Molecular Stratification of Cancer in the Clinical Setting David Gonzalez de Castro Molecular Diagnostics NHS FT and The Institute of Cancer Research, London, UK 1 2 The complexity of human cancer genomes